Amendola, a nationally recognized, award-winning healthcare technology and life sciences public relations and marketing firm, announced today that MDClone, a digital health company and leader in synthetic data, has selected the firm to amplify client successes, thought leadership, and industry best practices.
Amendola is implementing comprehensive PR and media plans to demonstrate MDClone’s industry-leading technology and services, new offerings, accomplishments, customer wins, and industry partnerships.
Also Read: Facemoji Keyboard’s New Features Let Users Text With Style
“Healthcare organizations have a strong need for real-world data to inform research initiatives, but often struggle to access it due to restrictive privacy laws and fragmented, incomplete patient records,” said Erin Giegling, vice president of marketing, MDClone. “Our partnership with Amendola will enable us to educate the industry on the value of accessing healthcare data by showcasing our ability to help clients deliver better outcomes through privacy-enabled shared data sets.”
“MDClone is dedicated to empowering healthcare organizations with the tools, processes, and services they need to translate data into better outcomes,” said Amendola CEO Jodi Amendola. “We are excited to collaborate with MDClone to amplify its accomplishments in enabling health systems and life sciences companies to maximize data utility while maintaining patient privacy.”
MDClone was founded in Israel in 2016. The MDClone ADAMS Platform includes innovative data publishing capabilities that further enhance the protection of patient privacy. MDClone’s unique technology enables any user of a healthcare organization to organize, access, and protect the privacy of patient data, empowering healthcare workers to rapidly transform ideas into actionable insights and take action.
Recently, MDClone was awarded Best Healthcare Big Data Platform by the MedTech Breakthrough Awards in 2021 and 2022. MDClone was also selected as a Technology Pioneer by the World Economic Forum in 2021 for the powerful MDClone ADAMS Platform.
MDClone is backed by some of the most prominent investors in the U.S. and Israel, including: aMoon, Lightspeed, OrbiMed, Warburg Pincus, and Viola Growth.
SOURCE: PR Newswire
Comments are closed.